DERIVATIVES OF 1, 2, 4-THIADIAZOLE, BASED ON IT PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION AS MODULATOR OF MELANOCORTIN RECEPTORS

FIELD: medicine; pharmacology. ^ SUBSTANCE: invention relates to the novel derivatives of 1,2,4-thiadiazole-2-il formula (I), , where R1, R2 and R4 present the radicals containing cyclic fragments, R3 designates hydrogen, alkyl, alkenyl or alkinyl that can be used as the agonists and antagonists of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LI DEHNIEHL KH, ZHAO BOJU, AJZINGER MAGDALENA, FITTSPATRIK LUIS DZH, PAN KEVIN, PLATA-SALAMAN KARLOS, REJTTS ALLEN B, SMIT-SVINTOSKI VIRDZHINIJA L
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY DEAF-AID SETS ELECTRIC COMMUNICATION TECHNIQUE ELECTRICITY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKEACOUSTIC ELECTROMECHANICAL TRANSDUCERS MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PUBLIC ADDRESS SYSTEMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: medicine; pharmacology. ^ SUBSTANCE: invention relates to the novel derivatives of 1,2,4-thiadiazole-2-il formula (I), , where R1, R2 and R4 present the radicals containing cyclic fragments, R3 designates hydrogen, alkyl, alkenyl or alkinyl that can be used as the agonists and antagonists of melanokortin receptors. Also, in this invention, the pharmaceutical composition, which shows the activity of modulator of melanokortin receptors, and the method of its preparation, are described. The purpose of this invention is to obtain the pharmaceutical compositions, which contain the therapeutically effective amount of compounds, as well as the pharmaceutically acceptable carrier, which are administered to the subject that suffers the melanokortin-mediated diseases, from the group with metabolic disturbances, abnormalities related to CNS and dermatologic abnormalities. ^ EFFECT: compounds can be used in treatment of CNS and dermatologic diseases. ^ 21 cl, 13 ex, 13 tbl